Company profile
PulmoBioMed Ltd
Pulmobiomed has developed a best-in-class exhaled breath condensate device, capable of capturing Covid-19 particles in as little as 5 seconds. Pulmobiomed a biotechnology company is working with industry leaders in integrating their diagnostic capabilities into our PBM-Hale device. Pulmobiomed technology can be used to sample people with covid-19 and the environment.
Financial period: 1 May 2024 to 30 Apr 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQzNjQ5MzkwOGFkaXF6a2N4
Published 19 Sep 2024 07:48
Company registered at Companies House
1 Dec 2023 to 31 Mar 2026
Breath contains materials from our lungs & mouths which are tell-tale signs of health or disease. Doctors could therefore replace sampling that requires lung surgery or intubation, with simple & safe breath samples. Capturing breath samples without contamination, in a consistent & reliable manner, has proven too difficult or expensive. The most advanced b...
1 Dec 2021 to 31 Jan 2022
For over 20 years researchers have shown that our breath contains materials from our lungs and our mouths which are tell-tale signs of health or disease. This means that doctors could one day replace needle-based blood tests with simple breath tests. However, doing this in a consistent and reliable manner has proven too difficult until now, which is why t...
